Latest news with #JamjoomPharma
Syyaha
30-07-2025
- Business
- Syyaha
New Agreement Brings Breakthrough Dyslipidemia Treatment to Saudi Arabia and MEA
Jamjoom Pharma, a leading Saudi pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products across MEA, and Althera Laboratories, a company dedicated to developing and commercializing innovative therapies for cardiovascular and metabolic diseases, today announced a strategic licensing and supply agreement. This agreement is poised to address the growing need for effective dyslipidemia management in the region, contributing to better patient outcomes and cardiovascular this agreement, Jamjoom Pharma gets exclusive rights to commercialize in Saudi Arabia and non-exclusive rights for phased expansion across other MEA markets for Althera's fixed-dose combination of dual-action cholesterol-lowering therapy. The product launch in Saudi Arabia is targeted for 2027, with plans for phased expansion across MEA markets, subject to local regulatory collaboration marks a major milestone for both companies: Jamjoom strengthens its cardiovascular portfolio with a globally recognized and clinically effective therapy, while Althera expands its international footprint in a high-growth partnership aims to address the region's growing burden of cardiovascular diseases by increasing access to modern, affordable lipid-lowering treatment, to support patients across Tarek Hosni, CEO of Jamjoom Pharma, highlighted that: 'Cardiovascular diseases remain to be a leading health concern in Saudi Arabia and the wider MEA region, and this partnership enables us to provide patients across the MEA region with an innovative, evidence-based solution. Expanding access to effective cholesterol management aligns perfectly with our promise to deliver high-quality, affordable medications that improve lives.' Sanjeev Agarwal, CEO of Althera added 'This partnership with Jamjoom Pharma is a pivotal step for Althera, allowing us to extend our reach into the rapidly growing MENA region. We are confident that Jamjoom's deep market understanding and robust capabilities make them the perfect partner to deliver our Rproduct to healthcare providers and patients in Saudi Arabia and across MENA. This collaboration is a testament to our dedication to making innovative and affordable cardiovascular treatments more accessible globally.'
Zawya
30-07-2025
- Business
- Zawya
New agreement brings breakthrough dyslipidemia treatment to Saudi Arabia and MEA
JEDDAH – Jamjoom Pharma, a leading Saudi pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products across MEA, and Althera Laboratories, a company dedicated to developing and commercializing innovative therapies for cardiovascular and metabolic diseases, today announced a strategic licensing and supply agreement. This agreement is poised to address the growing need for effective dyslipidemia management in the region, contributing to better patient outcomes and cardiovascular health. Under this agreement, Jamjoom Pharma gets exclusive rights to commercialize in Saudi Arabia and non-exclusive rights for phased expansion across other MEA markets for Althera's fixed-dose combination of dual-action cholesterol-lowering therapy. The product launch in Saudi Arabia is targeted for 2027, with plans for phased expansion across MEA markets, subject to local regulatory approvals. This collaboration marks a major milestone for both companies: Jamjoom strengthens its cardiovascular portfolio with a globally recognized and clinically effective therapy, while Althera expands its international footprint in a high-growth region. The partnership aims to address the region's growing burden of cardiovascular diseases by increasing access to modern, affordable lipid-lowering treatment, to support patients across MEA. Dr. Tarek Hosni, CEO of Jamjoom Pharma, highlighted that: 'Cardiovascular diseases remain to be a leading health concern in Saudi Arabia and the wider MEA region, and this partnership enables us to provide patients across the MEA region with an innovative, evidence-based solution. Expanding access to effective cholesterol management aligns perfectly with our promise to deliver high-quality, affordable medications that improve lives.' Sanjeev Agarwal, CEO of Althera added " This partnership with Jamjoom Pharma is a pivotal step for Althera, allowing us to extend our reach into the rapidly growing MENA region. We are confident that Jamjoom's deep market understanding and robust capabilities make them the perfect partner to deliver our Rproduct to healthcare providers and patients in Saudi Arabia and across MENA. This collaboration is a testament to our dedication to making innovative and affordable cardiovascular treatments more accessible globally." About Althera: Founded in 2010, Althera focuses on developing, out-licensing, manufacturing and supplying high value branded and select complex generic medicines. Althera pioneers innovative value added combinations fostering benefits throughout the value chain resulting in benefits for our partners, payers, prescribers and patients particularly in heart disease, diabetes and obesity management. Althera is headquartered in Dublin, Ireland. About Jamjoom Pharma 'Jamjoom Pharmaceuticals Factory Company': Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system. With a strong focus on patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition for more expansion, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine). Through its state-of-the-art facilities and established distribution channels across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.
Argaam
24-07-2025
- Business
- Argaam
Jamjoom Pharma ups profit margin forecast to 33%: CEO
Tarek Youssef Hosny, CEO of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma), said he expects the company to continue growth and achieve added value, saying that the forecast for the EBITDA margin for 2025 was raised to a range between 31.5-33%, from previous estimates of 30-31.5%, following the company's performance in the first half of the year. In an interview with Argaam, the top executive said that Jamjoom Pharma maintained its exceptional performance during H1 2025, attributing the continued growth to the strong momentum achieved in the first quarter, reflecting the resilience of its strategy in a dynamic operating environment, by focusing on strategic brands, improved operational efficiency, and disciplined cost management. He indicated that enhanced operational efficiency in research and development, manufacturing, and distribution contributed to boost profitability while maintaining a commitment to innovation and quality, adding that the company also continued to strengthen its key partnerships, launch new products, and continue its sustainability efforts. Meanwhile, the company's sales witnessed strong momentum across key markets during H1 2025. The Saudi market continued to drive growth, with revenues rising by 20.6% to SAR 577.8 million, accounting for more than two-thirds of the company's total revenue. Gulf markets accounted for SAR 107.7 million, led by the UAE and Oman, while sales in the Iraqi market grew by 27.3% to SAR 83.2 million, according to the top executive. He also highlighted that revenue from the Egyptian market grew by 12.8% in Egyptian pound, but declined when converted to Saudi riyals due to the depreciation of the Egyptian pound. Meanwhile, revenue from other export markets amounted to SAR 48.4 million, down 10% due to regional tensions in Jordan and Lebanon. However, export growth in Morocco and Libya helped mitigate the negative impact. Hosny also stated that the company is currently re-evaluating its distribution channels to ensure margin sustainability and achieve lower-risk growth in those markets. The company's H1 revenue was backed by several therapeutic areas, most notably general medicine, which grew by 37.7%. The ophthalmology and dermatology segments together accounted for 43.1% of topline. The diabetes drug portfolio grew by 71.5%, while cardiovascular treatments saw a 31.1% increase in sales, he added. Total production at the company's three plants reached 86 million units during H1, topped by the Jeddah plant with 68 million units at a utilization rate of 90.5%. Production at the Egypt plant grew by 54.1%, reaching 14 million units. The new sterile products plant in Jeddah continued its expansion, doubling its annual output to 4 million units with a utilization rate of 32.2%, which supported supplies in ophthalmology and sterile product segments, according to the CEO. As regards the Algeria project, Hosny said the project contributed SAR 6.5 million to H1 profit, as part of the company's expansion strategy in North Africa, while leveraging local manufacturing to enhance efficiency and reduce costs. He noted that this provides a solid platform for future expansion into neighboring North and West African markets. He also highlighted that the company will continue expanding into high-value therapeutic areas, accelerating regional expansion initiatives, and strategically investing in research and development and business alliances, especially in its core focus areas, with disciplined spending and a scalable platform.
Gulf Today
12-07-2025
- Health
- Gulf Today
Dermatology campaign to focus on eczema prevention
A genetically-induced skin disease, commonest in boys and women shall be the centrepiece campaign of dermatologists in the UAE and a Saudi-Arabia-headquartered pharmaceutical firm, this academic year until July 2026. The partnership between the Emirates Dermatology Society (EDS) and the Jamjoom Pharma, which has branches in Dubai and Cairo, Egypt, was formalised with the July 4 signing of the Memorandum of Understanding (MoU) in the capital, way ahead of the 'ECZPLORE' September launch. It is 'ECZPLORE' because the campaign is about eczema. EDS president Dr. Ayman Al Naeem told Gulf Today on Friday: 'Eczema has become one of the most pressing skin health issues in the UAE. It affects one in five children and often gets worse, because of the heat, the humidity and the air-conditioning; generally our climate.' Referring to the EDS data, when enquired regarding the youngest and oldest patients, the gender ratio, and the prevalence in the country's multi-racial landscape, Al Naeem said: 'The condition can appear as early as the first few weeks of life, although such an early onset is rare.' Rare too, it is, among septuagenarians and octogenarians who have been found to also be suffering from the disease, which counts 'environmental factors' namely 'allergens, climate, stress and irritants,' particularly those with 'family history and mutations in skin barrier genes like filaggrin,' a protein – a as a cause. These, as in the 'Atopic Dermatitis Insights on Global Prevalence, Health Care Implications and the Impact of COVID-19,' Kyung Hee University College of Medicine (Seoul, South Korea) medical student-researcher Jiyen Oh, noted that by 2050, global incidence would be at 148 million cases 'with minimal change in the prevalence rate.' The research was published in 'The Lancet Respiratory Medicine.' Oh studied the co-relation of eczema, otherwise known as Atopic Dermatitis, with asthma and COVID-19. Oh wrote that the skin disease shall have higher incidences in 'high-income countries likely influenced by environmental factors, urbanisation and better diagnostic capabilities.' Al Naeem pointed out that a campaign is crucial because 'beyond the skin, eczema affects how children sleep, play, learn and interact. For many families, it is a daily emotional and physical struggle.' Jamjoom Pharma-Gulf/Levant/Export Markets general manager Dr. Samer Lezzaiq said they are looking forward at partnerships with relevant authorities and educational institutions even as 'five major schools across the five largest cities in the UAE will be targeted.' 'This campaign is a national call to action designed to reach over one million individuals through digital platforms, schools and on-ground events,' Lezzaiq added, stressing that these are necessary; for, apart from the basic general knowledge, 'guidance on lifestyle modifications' are key to help patients and their households. 'Selection of the five major schools will be randomised. Primary targets are children between two and 12 years old,' said Lezzaiq. He answered in the negative when asked if secondary and tertiary educational institutions were included, as teenagers and young adults may be eczema sufferers as well: 'The age group most affected are the ages two and 12. Secondary schools, colleges, and universities fall outside of the current scope.' From Al Naeem: 'The highest prevalence is typically seen during childhood. In terms of gender distribution, it is more common in boys. This trend shifts in adulthood, with a higher prevalence observed in women.' He repeated Lezzaiq's mention of alterations in lifestyle, pointing out that while 'eczema is not fully preventable, its onset and flare-ups can be significantly reduced' through stress management, early treatment, avoiding triggers, and maintaining a healthy skin barrier with the use of breathable clothing and moisturisers to protect the skin barrier. Other highlights of the MoU, the signing of which was witnessed by EDS vice president Dr. Muna Al Murrawi and EDS-Scientific Committee head Dr. Fatima Albreiki: n The delivery of educational tools which include colouring books to help understand their condition while storybooks foster empathy and hope. n The delivery of lifestyle magazines and quick guides for families, caregivers and other support individuals to complete lifestyle modification among the patients. n The delivery of resources and other materials for healthcare professionals.
Syyaha
07-07-2025
- Health
- Syyaha
More Than Skin Deep: A New Partnership to Ease the Hidden Burden of Eczema in the UAE
Eczema, often dismissed as 'just a skin problem,' affects far more than the skin. For thousands of children in the UAE – and the families who care for them – it's a relentless battle of itching, poor sleep, emotional distress, and social isolation. Parents stay up through the night tending to their children's wounds, while children miss school, avoid friendships, and battle anxiety at a young age. This invisible epidemic is robbing too many families of comfort, confidence, and peace of response to this growing healthcare challenge, Jamjoom Pharma and the Emirates Dermatology Society (EDS) have signed today a Memorandum of Understanding (MoU) to launch 'ECZPLORE' —a pioneering awareness campaign aimed at changing the way eczema is understood, managed, and supported in the UAE.'Eczema is not just a rash—it's a chronic disease that affects the entire family,' said Dr. Ayman Al Naeem, President of the Emirates Dermatology Society. 'We believe that early education and empathetic support can change the daily reality for children living with eczema. Recent studies suggest that 1 in 5 children in the UAE suffer from eczema, with over half of moderate-to-severe cases remaining uncontrolled. The condition not only disrupts sleep and school life, but also doubles the likelihood of anxiety and depression in caregivers, highlighting the urgent need for broader public awareness.'The ECZPLORE program will roll out nationwide through schools, clinics, and digital channels. It includes child-friendly materials like coloring books and storybooks, adult-focused guides and magazines, and tailored support for healthcare professionals—all designed to help families better understand the condition and how to lead an 'eczema-friendly' life.'At Jamjoom Pharma, our purpose is to serve patient well-being through knowledge, care, and community support,' said Dr. Samer Lezzaiq, General Manager – Gulf, Levant & Export Markets at Jamjoom Pharma. 'Through ECZPLORE, we aim to break the silence around eczema, equip caregivers with real tools, and give children the confidence to live without shame.'The partnership also extends into fungal infection awareness, targeting both patients and professionals with actionable educational campaigns. Together, Jamjoom Pharma and EDS hope to drive a cultural shift in how chronic skin conditions are perceived and managed, transforming frustration into understanding—and silence into support.
